Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Brandeis

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Pharmacology, Biochemistry, and Behavior|June 1, 1991
Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged ratsR Brandeis, M Sapir, Y Kapon, et al.
Annals of the New York Academy of Sciences|February 24, 2001
M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectivesA Fisher, D M Michaelson, R Brandeis, et al.
Pharmacology, Biochemistry, and Behavior|August 1, 1995
AF150(S): a new functionally selective M1 agonist improves cognitive performance in ratsR Brandeis, M Sapir, N Hafif, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 10, 2015
Synergism Between Anticholinergic and Oxime Treatments Against Sarin-Induced Ocular Insult in RatsA Gore, R Brandeis, I Egoz, et al.
Toxicology and Applied Pharmacology|November 8, 2005
Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving ratsE Gilat, T Kadar, A Levy, et al.
Neuroscience Letters|July 31, 1989
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated ratsA Fisher, R Brandeis, Z Pittel, et al.
Advances in Neurology|January 1, 1990
AF102B: rational treatment strategy for Alzheimer's disease: recent advancesA Fisher, R Brandeis, I Karton, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's diseaseA Fisher, R Brandeis, I Karton, et al.
Journal of Neural Transmission. Supplementum|November 29, 2002
Impact of muscarinic agonists for successful therapy of Alzheimer's diseaseA Fisher, R Brandeis, R Haring, et al.
Archives of Toxicology|March 13, 2003
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pigE Gilat, M Goldman, E Lahat, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Pharmacology, Biochemistry, and Behavior|June 1, 1991
Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged ratsR Brandeis, M Sapir, Y Kapon, et al.
Annals of the New York Academy of Sciences|February 24, 2001
M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectivesA Fisher, D M Michaelson, R Brandeis, et al.
Pharmacology, Biochemistry, and Behavior|August 1, 1995
AF150(S): a new functionally selective M1 agonist improves cognitive performance in ratsR Brandeis, M Sapir, N Hafif, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|May 10, 2015
Synergism Between Anticholinergic and Oxime Treatments Against Sarin-Induced Ocular Insult in RatsA Gore, R Brandeis, I Egoz, et al.
Toxicology and Applied Pharmacology|November 8, 2005
Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving ratsE Gilat, T Kadar, A Levy, et al.
Neuroscience Letters|July 31, 1989
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated ratsA Fisher, R Brandeis, Z Pittel, et al.
Advances in Neurology|January 1, 1990
AF102B: rational treatment strategy for Alzheimer's disease: recent advancesA Fisher, R Brandeis, I Karton, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 1991
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's diseaseA Fisher, R Brandeis, I Karton, et al.
Journal of Neural Transmission. Supplementum|November 29, 2002
Impact of muscarinic agonists for successful therapy of Alzheimer's diseaseA Fisher, R Brandeis, R Haring, et al.
Archives of Toxicology|March 13, 2003
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pigE Gilat, M Goldman, E Lahat, et al.
Pageof 3